Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Aflibercept and Bevacizumab in the Treatment of Type 1 Retinopathy of Prematurity Publisher



Riaziesfahani H1 ; Mahmoudi A1 ; Sanatkar M1 ; Farahani AD1 ; Bazvand F1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Science, Tehran, Iran

Source: International Journal of Retina and Vitreous Published:2021


Abstract

Background: To evaluate the outcome of intravitreal bevacizumab (IVB) and aflibercept (IVA) injection for patients with retinopathy of prematurity (ROP). Methods: In this single-center retrospective cohort, the recorded medical data of the infants who had been undergone intravitreal injection with either bevacizumab or aflibercept for type 1 ROP were reviewed. The infants were allocated into two groups. IVB group included patients who were treated with bevacizumab as initial treatment and the IVA group included patients who were treated with aflibercept as initial treatment. The rate and time of complete regression, as well as the recurrence rates, were compared between the groups. Results: A total of 889 eyes of 453 infants were enrolled in the study. There were 865 eyes of 441 infants in the IVB group and 24 eyes of 12 infants in the IVA group. Follow-up time was 289 ± 257 days in the IVB group and 143 ± 25 days in the IVA group (p < 0.001). The difference in the ROP zone was not statistically significant between the 2 treatment groups (p = 0.328). All eyes in the IVA group showed initial regression of ROP after the intravitreal injections. These regressions were achieved in 830 (96.0%) eyes that were injected with IVB (p = 0.023). The median observed regression time was 10 days and 16 days in eyes treated with bevacizumab and aflibercept respectively. Recurrence was noted in 3.9% of eyes (34/865) in the IVB group and 58.3% of eyes (14/24) in the IVA group (p < 0.001). Conclusion: While the regression rate in the IVA group was significantly higher than in the IVB group, the recurrence rate was significantly more in the IVA group, which may be attributed to differences in the pharmacokinetics of these drugs in the vitreous body. © 2021, The Author(s).
Related Docs
View other Related Docs
1. Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity, Ophthalmology Retina (2018)
2. Progression of Retinal Vascularization After Intravitreal Anti-Vascular-Endothelial Growth Factor Therapy in Retinopathy of Prematurity, International Journal of Retina and Vitreous (2022)
3. Intravitreal Bevacizumab to Treat Retinopathy of Prematurity in 865 Eyes: A Study to Determine Predictors of Primary Treatment Failure and Recurrence, International Ophthalmology (2022)
4. Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity, Journal of Ophthalmic and Vision Research (2018)
5. Ketamine Analgesia As an Alternative to General Anesthesia During Laser Treatment for Retinopathy of Prematurity, Journal of Pediatric Ophthalmology and Strabismus (2022)
6. Evaluation of Neurodevelopmental Outcomes in Premature Twins (Multigestations) With Retinopathy of Prematurity Receiving Anti-Vegf: A Comparison Study, Journal of Ophthalmology (2022)
7. Parenteral Fish-Oil Lipid Emulsions in Retinopathy of Prematurity: A Retrospective Comparative Study, Journal of Current Ophthalmology (2020)
8. Hypertension and Ischemic Stroke After Aflibercept for Retinopathy of Prematurity, International Medical Case Reports Journal (2020)
Experts (# of related papers)
View all Related Experts
Fatemeh Bazvand (6)
Hamid Riazi-Esfahani (5)
Other Related Docs
9. Retinal and Choroidal Neovascularization Antivascular Endothelial Growth Factor Treatments: The Role of Gene Therapy, Journal of Ocular Pharmacology and Therapeutics (2022)
10. Ocular Complications Following Intravitreal Bevacizumab Injection for Retinopathy of Prematurity and Assessment of Risk Factors, International Journal of Retina and Vitreous (2021)
11. Comparison of Intravitreal Bevacizumab Injection and Laser Photocoagulation for Type 1 Zone Ii Retinopathy of Prematurity, Journal of Current Ophthalmology (2019)